Circulating microRNAs in plasma before and after radical prostatectomy

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Circulating microRNAs (miRNAs) are being investigated as non-invasive biomarkers for various cancers, including prostate cancer.
• The diagnostic and prognostic utility of plasma miRNAs in prostate cancer, particularly in relation to treatment outcomes like radical prostatectomy (RP), requires further elucidation.

Purpose of the Study:

• To determine if circulating miRNAs in plasma can serve as biomarkers for prostate cancer in men undergoing radical prostatectomy (RP).
• To examine the expression levels of specific miRNAs before and after RP and correlate them with disease characteristics.

Main Methods:

• Real-time PCR was used to analyze the expression of 17 preselected circulating miRNAs in plasma from prostate cancer patients before and after RP.
• Statistical analyses, including Wilcoxon signed-ranked and rank sum tests, were employed to compare miRNA expression based on treatment status and disease characteristics (pathologic tumor stage, Gleason score).
• Partial correlation was used to assess the relationship between miRNA expression and serum prostate-specific antigen (PSA) levels.

Main Results:

• No significant changes in plasma miRNA expression were observed between pre- and post-RP samples.
• Higher expression of miR-34a, miR-378, and miR-450b-5p was detected in pre-RP plasma of patients with advanced pathologic tumor stage (T3) compared to those with lower stage (T2).
• No statistically significant correlations were found between the expression of these circulating miRNAs and Gleason score or serum PSA levels at the time of RP.

Conclusions:

• Circulating miRNA expression in plasma did not significantly change in the early post-operative period (approximately 2 months) following radical prostatectomy.
• Elevated levels of miR-34a, miR-378, and miR-450b-5p in pre-RP plasma may indicate more advanced prostate cancer.
• Further longitudinal studies with longer follow-up are necessary to fully evaluate the diagnostic potential of circulating miRNAs in prostate cancer management.